Compare · BDX vs LUCD
BDX vs LUCD
Side-by-side comparison of Becton Dickinson and Company (BDX) and Lucid Diagnostics Inc. (LUCD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and LUCD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $57.96B, about 764.0x LUCD ($75.9M).
- BDX has been more active in the news (11 items in the past 4 weeks vs 7 for LUCD).
- BDX has more recent analyst coverage (25 ratings vs 6 for LUCD).
- Company
- Becton Dickinson and Company
- Lucid Diagnostics Inc.
- Price
- -
- -
- Market cap
- $57.96B
- $75.9M
- 1M return
- +5.96%
- -
- 1Y return
- +41.40%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 11
- 7
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest BDX
- BD Marks 85 Years of Essential Medical Device Manufacturing in Glen Falls, NY
- BD Named to TIME's 2027 List of America's Top Manufacturers
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
Latest LUCD
- PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
- SEC Form 10-Q filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
- Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
- PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
- Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
- Oil Above $100 Puts Penny Stocks in Focus